GEMP News and Press, Gemphire Therapeutics Inc.

NeuroBo Pharmaceuticals (NRBO) perks up 6% premarket after receiving approval of an amendment to its Contingent Value Rights ((CVR)) agreement from a majority of CVR holders. The CVRs were distributed to the holders of Gemphire Therapeutics (GEMP) common stock on December 30, 2019, ...

ANN ARBOR, Mich., Dec. 30, 2019 (GLOBE NEWSWIRE) -- The pending merger between Gemphire Therapeutics Inc. (NASDAQ:GEMP) and NeuroBo Pharmaceuticals, Inc. is currently expected to close after market hours today, Monday, December 30, 2019, subject to satisfaction or waiver of all closing cond...

Gemphire Therapeutics' (NASDAQ: GEMP ) stockholders have approved all of the NeuroBo merger-related proposals, including: (i) the issuance of Gemphire common stock pursuant to the Agreement dated July 24, (ii) a reverse stock split of Gemphire common stock, at a ratio of one new share...

ANN ARBOR, Mich., Dec. 06, 2019 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP) announced today that, based upon the final vote count certified by the independent inspector of elections for the annual meeting of stockholders held December 6, 2019, its stockholders approved all ...

Gemphire Therapeutics (NASDAQ: GEMP ): Q2 GAAP EPS of -$0.20  misses by $0.08 . More news on: Gemphire Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

LIVONIA, Mich., Aug. 09, 2019 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life-threatening cardiova...

The Clinical Misjudgement Gemphire ( GEMP ) is a clinical-stage biopharma that became a victim of its presumed success. It all started with its decision not to recognise its lead and sole investigative drug candidate, gemcabene, as a PPAR-α agonist. Despite the fact that gemcabene (...

Gemphire Therapeutics (NASDAQ: GEMP ) and privately held NeuroBo Pharmaceuticals have agreed to merge . The combined company will do business as NeuroBo Pharmaceuticals, Inc. and will trade under the ticker "NRBO." More news on: Gemphire Therapeutics Inc., Healthcare stocks news, Merger &...

Transaction to Create Nasdaq-listed Biotechnology Company Focused on Advancing NeuroBo’s Clinical-Stage Pipeline NeuroBo Poised to Advance Lead Drug Candidate into Phase 3 Trials for Neuropathic Pain Indications NeuroBo Recently Received Aggregate Gross Proceeds of $24.24 M...

Thinly traded nano cap Gemphire Therapeutics (NASDAQ: GEMP ) is down  6%  premarket in reaction to results from five-subject open-label proof-of-concept (POC) study evaluating gemcabene in patients with a rare inherited fatty tissue disorder called familial partial lipodystrophy ...